IDWeek 2021 will showcase scientific progress in infectious diseases

AstraZeneca will present data across its Covid-19 and respiratory syncytial virus (RSV) pipeline as three late-breaking oral presentations at the 10th Annual IDWeek Virtual Conference, September 29 to October 3, 2021, illustrating its commitment to advancing innovative science in infectious diseases. 

The presentations include AZD7442 long-acting antibody combination Phase III PROVENT trial prevention data and Vaxzevria Phase III analysis investigating asymptomatic infection and duration of viral shedding in infections. 

Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said: “The compelling data being presented at IDWeek reflect our scientific advances across infectious diseases in response to the Covid-19 pandemic and surges in respiratory syncytial virus cases. Our PROVENT Phase III data demonstrate AZD7442 may offer much-needed protection for vulnerable populations who may not mount an adequate immune response to Covid-19 vaccination.” 

The Phase III PROVENT trial data showed that AZD7442 compared to placebo achieved a statistically significant reduction in the risk of developing symptomatic Covid-19 prior to virus exposure (pre-exposure prophylaxis).1 More than 75% of participants in the trial had co-morbidities, which includes those with a reduced immune response to vaccination.1 In PROVENT, the LAAB was well tolerated and preliminary analyses show adverse events were balanced between the placebo and AZD7442 groups. 

A late-breaker oral presentation of Phase III results will show whether Vaxzevria prevents asymptomatic cases of Covid-19, as well as its capability to shorten viral shedding in breakthrough infections. Understanding the duration of viral shedding may help the implementation of effective public health efforts to control the spread of the virus.2 

The MELODY Phase III trial data for nirsevimab, an investigational long-acting antibody being developed by AstraZeneca and Sanofi, will demonstrate the potential of nirsevimab to help protect all infants entering their first RSV season with a single dose. 

References 

  1. AstraZeneca news release. AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19. Available at: https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/azd7442-prophylaxis-trial-met-primary-endpoint.html. [Last accessed: September 2021] 
  2. Public Health England. COVID-19 vaccine surveillance report Week 27. 2021 Jul. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1000512/Vaccine_surveillance_report_-_week_27.pdf [Last accessed: September 2021] 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free